1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > In-Vitro Diagnostics (IVD) Market Analysis and Segment Forecasts To 2020

The global market for IVD is expected to reach USD 74.32 billion by 2020. Constantly improving patient awareness levels pertaining to infectious diseases and their subsequent diagnosis, the introduction of advanced molecular and tissue diagnostic tests for cancer such as companion diagnostics and the growing global base of geriatric population are some of the primary drivers for this market. Moreover, rising global healthcare expenditures, especially in Asia Pacific and increasing demand for rapid, minimally invasive and non-invasive diagnostic procedures are also expected to have a positive impact on market growth. The emergence of epigenomics-based diagnostics and the ability of molecular diagnostics to detect disease at an early stage of development are expected to create opportunity for industry participants to capitalize on over the next six years.

The professional diagnostic products dominated the overall IVD market in 2013, owing to the high usage rates of these tests in diagnostic tests pertaining to the infectious disease segment, and are expected to grow at a CAGR of 4.7% from 2014 to 2020 to reach an estimated value of USD 49.76 billion by 2020. However, the tissue diagnostics market is expected to grow at the highest CAGR of 10.2% from 2014 to 2020, owing to its growing application in cancer diagnosis and need for lab automation as a consequence of limited skilled labor availability.

Further Key findings from the study suggest:

North America is expected to dominate the overall market throughout the forecast period, majorly on account of the presence of sophisticated healthcare infrastructure, high patient awareness levels and improving reimbursement frameworks, with revenue estimated to reach USD 28.79 billion by 2020.

Asia Pacific is expected to be the fastest growing regional market for IVD, at an estimated CAGR of 7.4% from 2014 to 2020. The presence of high unmet medical needs for cancer and infectious diseases and a constantly improving healthcare infrastructure in emerging markets such as China and India are some of the drivers of this market.

The global molecular diagnostics market is expected to follow the tissue diagnostics segment in terms of growth during the forecast period, owing to the growing demand for advanced genetic and HPV diagnostic tests.

Its market is expected to grow at a CAGR of 8.7% from 2014 to 2020.

Some of the key players of this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, bioMerieux, Beckman Coulter Inc., Becton Dickinson and others

For the purpose of this study, Grand View Research has segmented the global IVD market on the basis of product and region:

- IVD Market Product Outlook
- Molecular Diagnostics
- Tissue Diagnostics
- Diabetes Monitoring
- Professional Diagnostics
- IVD Market Regional Outlook
- North America
- Europe
- Asia Pacific
- RoW

Table Of Contents

In-Vitro Diagnostics (IVD) Market Analysis and Segment Forecasts To 2020
Table of Contents

Chapter 1. Executive Summary

1.1. IVD - Industry Summary and Critical Success Factors (CSFs)

Chapter 2. IVD Industry Outlook

2.1. Market Segmentation

2.2. Market Size and Growth Prospects

2.3. IVD Market Dynamics

2.4. Key Opportunities Prioritized

2.5. Industry Analysis - Porter's

2.6. Molecular Diagnostics - Company Market Share Analysis

2.7. Tissue Diagnostics - Company Market Share Analysis

2.8. Professional Diagnostics - Company Market Share Analysis

2.9. Diabetes Monitoring - Company Market Share Analysis

2.10. IVD Market PESTEL Analysis, 2012

Chapter 3. IVD Product Outlook

3.1. Molecular Diagnostics

3.2. Tissue Diagnostics

3.3. Diabetes Monitoring

3.4. Professional Diagnostics

Chapter 4. IVD Regional Outlook

4.1. North America

4.2. Europe

4.3. Asia-Pacific

4.4. RoW

Chapter 5. Competitive Landscape

5.1 Abbott Laboratories

5.1.1 Company Overview

5.1.2 Financial Performance

5.1.3 Product Benchmarking

5.1.4 Strategic Initiatives

5.2 Roche Diagnostics

5.2.1 Company Overview

5.2.2 Financial Performance

5.2.3 Product Benchmarking

5.2.4 Strategic Initiatives

5.3 Siemens Healthcare

5.3.1 Company Overview

5.3.2 Financial Performance

5.3.3 Product Benchmarking

5.3.4 Strategic Initiatives

5.4 Johnson and Johnson

5.4.1 Company Overview

5.4.2 Financial Performance

5.4.3 Product Benchmarking

5.4.4 Strategic Initiatives

5.5 Bio-Rad Laboratories

5.5.1 Company Overview

5.5.2 Financial Performance

5.5.3 Product Benchmarking

5.5.4 Strategic Initiatives

5.6 Beckman Coulter Inc.

5.6.1 Company Overview

5.6.2 Financial Performance

5.6.3 Product Benchmarking

5.6.4 Strategic Initiatives

5.7 Becton Dickinson

5.7.1 Company Overview

5.7.2 Financial Performance

5.7.3 Product Benchmarking

5.7.4 Strategic Initiatives

5.8 bioMerieux

5.8.1 Company Overview

5.8.2 Financial Performance

5.8.3 Product Benchmarking

5.8.4 Strategic Initiatives

5.9 Sysmex

5.9.1 Company Overview

5.9.2 Financial Performance

5.9.3 Product Benchmarking

5.9.4 Strategic Initiatives

5.10 Bayer Healthcare

5.10.1 Company Overview

5.10.2 Financial Performance

5.10.3 Product Benchmarking

5.10.4 Strategic Initiatives

5.11 Alere Inc.

5.11 .1 Company Overview

5.11.2 Financial Performance

5.11.3 Product Benchmarking

5.11.4 Strategic Initiatives

5.12 Danaher Corporation

5.12.1 Company Overview

5.12.2 Financial Performance

5.12.3 Product Benchmarking

5.12.4 Strategic Initiatives

5.13 Hologic (Gen-Probe)

5.13.1 Company Overview

5.13.2 Financial Performance

5.13.3 Product Benchmarking

5.13.4 Strategic Initiatives

5.14 Novartis

5.14.1 Company Overview

5.14.2 Financial Performance

5.14.3 Product Benchmarking

5.14.4 Strategic Initiatives

5.15 Cepheid

5.15.1 Company Overview

5.15.2 Financial Performance

5.15.3 Product Benchmarking

5.15.4 Strategic Initiatives

5.16 Qiagen

5.16.1 Company Overview

5.16.2 Financial Performance

5.16.3 Product Benchmarking

5.16.4 Strategic Initiatives

5.17 Leica Biosystems

5.17.1 Company Overview

5.17.2 Financial Performance

5.17.3 Product Benchmarking

5.17.4 Strategic Initiatives

5.18 Dako

5.18.1 Company Overview

5.18.2 Financial Performance

5.18.3 Product Benchmarking

5.18.4 Strategic Initiatives

Chapter 6. Methodology and Scope

6.1. Research Methodology

6.2. Research Scope and Assumption

6.3. List of Data Sources


List of Tables

1. IVD - Industry Summary and Critical Success Factors (CSFs)
2. Global IVD Revenue, 2012 - 2020 (USD million)
3. Global IVD Market Revenue by Region, (USD million), 2012 - 2020
4. Global IVD Market Revenue by Products, (USD million), 2012 - 2020
5. Global Tissue Diagnostics Demand, 2012 to 2020 (USD million)
6. Global Tissue Diagnostics Demand, by Region, 2012 to 2020 (USD million)
7. Global Molecular Diagnostics Demand, 2012 to 2020 (USD million)
8. Global Molecular Diagnostics Demand, by Region, 2012 to 2020 (USD million)
9. Global Professional Diagnostics Demand, 2012 to 2020 (USD million)
10. Global Professional Diagnostics Demand, by Region, 2012 to 2020 (USD million)
11. Global Diabetes Monitoring Demand, 2012 to 2020 (USD million)
12. Global Diabetes Monitoring Demand, by Region, 2012 to 2020 (USD million)
13. North America IVD demand, by Products, (USD million), 2012 - 2020
14. Europe IVD demand, by Products, (USD million), 2012 - 2020
15. Asia Pacific IVD demand, by Products, (USD million), 2012 - 2020
16. RoW IVD demand, by Products, (USD million), 2012 - 2020


List of Figures

1. IVD Market Segmentation
2. Global IVD Market Revenue, 2012 - 2020
3. IVD Market Dynamics
4. Global population base over the age group of 60 years, 2010 and 2017 (million)
5. Global diabetes prevalence, 2010 and 2017 (million)
6. Molecular Diagnostics Company Market Share Analysis, 2012
7. Tissue Diagnostics Company Market Share Analysis, 2012
8. Professional Diagnostics Company Market Share Analysis, 2012
9. Diabetes Monitoring Company Market Share Analysis, 2012
10. Key Opportunities Prioritized
11. Industry Analysis - Porter's
12. IVD PESTEL Analysis, 2012
13. Global IVD Revenue, by Products, 2012 and 2020
14. Global Molecular Diagnostics Demand, by Region, 2012 to 2020 (USD million)
15. Global Tissue Diagnostics Demand, by Region, 2012 to 2020 (USD million)
16. Global Professional Diagnostics Demand, by Region, 2012 to 2020 (USD million)
17. Global Diabetes Monitoring Demand, by Region, 2012 to 2020 (USD million)
18. North America IVD Demand, by Products, 2012 to 2020 (USD million)
19. Europe IVD Demand, by Products, 2012 to 2020 (USD million)
20. Asia Pacific IVD Demand, by Products, 2012 to 2020 (USD million)
21. RoW IVD Demand, by Products, 2012 to 2020 (USD million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.